Radical Improvement of Cancer Treatment without Additional Negative Side Effectsbroad
HyperCollar4D · Horizon Europe grant · 2022-01-01–2025-06-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATORCHALLENGES-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01. CORDIS record →
Objective
We have developed a device called HyperCollar4D that significantly increases the effectiveness of radiotherapy for head and neck (H&N) cancer. The first results on 70 patients have proven that our technology yields +50% complete response with respect to radiotherapy alone. The HyperCollar4D is based on hyperthermia: warming up the tumor to 43 C improves its sensitivity to radiotherapy. Hyperthermia yields no lasting toxicity, unlike radiotherapy and chemotherapy. The challenge with hyperthermia is delivering it effectively (i.e., heating only the tumor and not the nearby tissues) and cost-efficiently. The HyperCollar4D is the first device to achieve effective and cost-efficient hyperthermia treatments for H&N cancer. Our technology (called thermotherapy) is protected by two patents (one granted and one filed). The HyperCollar4D design is modular, so it can be extended to add modules to treat other kinds of cancers. Sensius is a spin-off of the Erasmus Medical Center.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| SENSIUS BV | NL | coordinator | €2,500,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.